Response

Affiliations

¹ Centre of Respiratory Medicine, University College London, Royal Free Campus, London, England. Electronic address: j.wedzicha@ucl.ac.uk.
² Krakenhaus Grosshansdorf, Center for Pulmonology and Thoracic Surgery, Grosshansdorf, Germany.
³ Department of Internal Medicine, University of Michigan Medical Center Ann Arbor, MI.
⁴ Department of Respiratory Medicine, Nycomed: a Takeda Company, Konstanz, Germany.
⁵ Department of Analytical Science, Takeda Pharmaceuticals International GmbH.
⁶ University of Liverpool, Liverpool, England.

Comment

Jadwiga A Wedzicha et al. Chest. 2014 Feb.

. 2014 Feb;145(2):428.

doi: 10.1378/chest.13-2535.

¹ Centre of Respiratory Medicine, University College London, Royal Free Campus, London, England. Electronic address: j.wedzicha@ucl.ac.uk.
² Krakenhaus Grosshansdorf, Center for Pulmonology and Thoracic Surgery, Grosshansdorf, Germany.
³ Department of Internal Medicine, University of Michigan Medical Center Ann Arbor, MI.
⁴ Department of Respiratory Medicine, Nycomed: a Takeda Company, Konstanz, Germany.
⁵ Department of Analytical Science, Takeda Pharmaceuticals International GmbH.
⁶ University of Liverpool, Liverpool, England.

No abstract available

Comment on

Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
Wedzicha JA, Rabe KF, Martinez FJ, Bredenbröker D, Brose M, Goehring UM, Calverley PMA. Wedzicha JA, et al. Chest. 2013 May;143(5):1302-1311. doi: 10.1378/chest.12-1489. Chest. 2013. PMID: 23117188 Clinical Trial.
Evidence roflumilast reduces severe exacerbations?
Coyle T. Coyle T. Chest. 2014 Feb;145(2):427-428. doi: 10.1378/chest.13-2283. Chest. 2014. PMID: 24493538 No abstract available.